

# **MedTech Funding Mandate (MTFM) and placental growth factor (PIGF)-based testing**

Review of guidance for NHS commissioners  
and providers 2021/22

[www.england.nhs.uk/aac/wp-content/uploads/sites/50/2021/01/mtfm-policy-guidance-jan-2021.pdf](http://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2021/01/mtfm-policy-guidance-jan-2021.pdf)

# Overview of MTFM policy - general



- In the [NHS long term plan](#)<sup>1</sup>, NHS England and NHS improvement outlined how research and innovation would drive better outcomes and experience for patients.
- Commitment to introduce a MTFM to accelerate the uptake of selected NICE-approved, cost-saving medical devices, diagnostics and digital products in the NHS, meaning patients will get access to these technologies faster.
- Technologies included in the MTFM have been proven to support safe and effective care and this can be evidenced as part of a Care Quality Commission inspection.
- The Roche Diagnostics Elecsys<sup>®</sup> sFlt-1/PIGF ratio test is one of the products that have been included in the MTFM.

1. NHS long term plan: [www.longtermplan.nhs.uk](http://www.longtermplan.nhs.uk) (accessed Feb 2021)

# Overview of MTFM policy - general



- The **NHS standard contract** will require both commissioners and providers of NHS-funded services to comply with their obligations under the MTFM.
- The accelerated access collaborative (AAC) will continue to work with product suppliers and will track the uptake of PIGF-based testing and this will be monitored through the AAC board.

# Overview of MTFM policy - funding and commissioning

- The MTFM does not directly fund the technologies included in the policy.
- NHS-funded care providers will be reimbursed by their commissioner.
- NTPS (National Tariff Payment System)<sup>1</sup>, Annex A, lists the technologies in the MTFM policy, called the innovative products list. Items on this list are excluded from national prices and reimbursed by NHS commissioner.
- For the MTFM, this would have impact in the first year of implementation: for any technologies supported by the policy, the activity and cost would be agreed between providers and commissioners and added to the *fixed payment*. This would enable providers to understand their levels of funding upfront, to aid planning

1. [www.england.nhs.uk/publication/national-tariff-payment-system-documents-annexes-and-supporting-documents/](http://www.england.nhs.uk/publication/national-tariff-payment-system-documents-annexes-and-supporting-documents/)


# MTFM and NHS service providers



Make provision for changes to payment flows when ITT/ITP (Innovation and Technology Tariff/Payment programme) support ends on 31 March 2021:

- Agree local processes with commissioners to implement these technologies. This may be done by engaging commissioning (usually in finance) and costing teams to plan your current and future contracting arrangements.
- Provide an overview of spend and support discussions with CCGs (Clinical Commissioning Groups) and their reimbursement plans, we would still encourage sites to produce a business case/plan and involve their CCGs as soon as possible

# An example of pathway for agreement on funding



Redrawn. Original image from Guy Checketts Head of Transformation and Evaluation Oxford Academic Health Science Network



# Example of reimbursement pathway



Redrawn. Original image from Guy Checketts Head of Transformation and Evaluation Oxford Academic Health Science Network



# PIGF-based tests



Providers adopting this technology must<sup>1</sup>:

- Integrate PIGF-based testing into the local pre-eclampsia pathway;
- Offer PIGF-based testing to all suitable pregnant women, as defined by NICE DG23<sup>2</sup> and adhere to relevant clinical guidelines;
- Engage all appropriate clinical staff in training; pathway and test interpretation;
- Ensure that staff who perform PIGF-based tests have been trained and accredited;
- Have access to an appropriate platform on which to process the test;
- Ensure that staff perform the test in line with the recommendations provided by the supplier;
- Use PIGF-based tests in accordance with the system information package inserts.


1. [www.england.nhs.uk/aac/wp-content/uploads/sites/50/2021/01/mtfm-policy-guidance-jan-2021.pdf](http://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2021/01/mtfm-policy-guidance-jan-2021.pdf) (page 28); 2. NICE DG23: [www.nice.org.uk/guidance/dg23/chapter/1-Recommendations](http://www.nice.org.uk/guidance/dg23/chapter/1-Recommendations) (accessed Feb 2021)



# Contact details



*Dedicated inbox:*  
*[burgesshill.accessinnovation@roche.com](mailto:burgesshill.accessinnovation@roche.com)*



© 2021 Roche Diagnostics Limited. All rights reserved.

ELECSYS and COBAS are trademarks of Roche. All other trademarks or brand names are the property of their respective owners.

Roche Diagnostics Limited, Charles Avenue, Burgess Hill, West Sussex, RH15 9RY, United Kingdom. Company Registration Number: 571546

Date of preparation: March 2021

Document number: MC-IE-01016

For healthcare professional use only in the UK and Ireland. Not for distribution.

[www.roche.co.uk](http://www.roche.co.uk)

**cobas**<sup>®</sup>

© 2021 Roche Diagnostics Limited. All rights reserved. For healthcare professional use only in the UK and Ireland. Not for distribution.

*Doing now what patients need next*